They Said There Was No Cure. Then a Jelly-Bean Device Sent Rheumatoid Arthritis Into Retreat — Without a Single Drug

For 38 years, Susan Perry’s immune system was destroying her from the inside. In February, a surgeon placed a device the size of a jelly bean on her vagus nerve. She hasn’t had a bad day since.

Susan Perry waited nearly four decades for something that worked.

Rheumatoid arthritis — the autoimmune disease where the body’s own immune system turns on its joints, cartilage, and tissue — had defined her adult life. The flare-ups. The fatigue. The medications that helped until they didn’t, then were swapped for other medications with their own side effects and their own expiration dates.

Then, in February 2026, Perry became the first person in Texas to receive the SetPoint System: a small neurostimulation implant, roughly the size of a jelly bean, placed directly on her vagus nerve.

It delivers one minute of electrical stimulation per day. No pills. No injections. No immunosuppressants.

“I keep waiting to have some bad days, but I’m not,” Perry told reporters. “I’m still amazed by it.”

She is not alone in her amazement. Neither should you be — because what just happened with the SetPoint System is not merely a new treatment for one disease. It is the opening move in what could become the most important shift in medicine since the invention of antibiotics.

What Is the Vagus Nerve, and Why Has No One Done This Before?

The vagus nerve is the longest cranial nerve in the body. It runs from your brainstem down through your neck, chest, and abdomen, connecting your brain to nearly every major organ — heart, lungs, liver, gut. It is the neural superhighway of the autonomic nervous system.

For most of medical history, it was understood primarily in terms of what it regulated: heart rate, digestion, breathing.

Then, in the 1990s, neurosurgeon Kevin Tracey — now president of the Feinstein Institutes for Medical Research at Northwell Health — made a discovery that upended that understanding entirely. While studying sepsis, Tracey observed that the vagus nerve wasn’t just a passive relay system. It actively controlled inflammation. When stimulated, it sent signals to the spleen, which then suppressed the production of tumor necrosis factor (TNF) — the same inflammatory protein that biologics like adalimumab (Humira) are designed to block, at enormous cost and systemic risk.

The body, it turned out, already had a built-in anti-inflammatory switch. Tracey had found the wiring.

He founded SetPoint Medical in 2007. It took nearly two decades of clinical development, regulatory navigation, and a pivotal 242-patient trial to get to where we are today.

That gap — between discovery and approval — is its own indictment of how slowly medicine moves when there’s no blockbuster drug to sell.

The FDA Said Yes. Here’s What the Data Actually Shows.

On July 31, 2025, the FDA granted premarket approval to the SetPoint System, making it the first implantable vagus nerve stimulation device cleared for rheumatoid arthritis in the United States — and the first non-drug treatment of any kind approved for the disease.

The approval rested on the RESET-RA trial: a randomized, double-blind, sham-controlled Phase 3 study enrolling 242 adults with moderate-to-severe RA. All participants had already failed at least one biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD). Sixty percent had what clinicians classify as difficult-to-treat RA — the category where standard medicine has essentially given up.

All 242 patients were implanted with the device. Half received active stimulation; half received sham stimulation. Neither the patients nor the evaluating physicians knew who got which.

At 12 weeks, 35.2% of the active group achieved ACR20 response — a standard rheumatology benchmark for meaningful symptom reduction — compared to 24.2% in the sham group. The gap is statistically significant (P = .0209), but the headline number that matters most is this: over 12 months, participants saw an average 60% improvement in tender and swollen joint counts. Three-quarters of trial participants achieved symptom relief without any additional therapy.

The safety profile was equally striking. The rate of serious adverse events related to the device or therapy was 1.7%. There were no observed malignancies, no major cardiac events, no serious infections attributable to the SetPoint System.

Compare that to the label on any biologic currently prescribed for RA. The difference is not subtle.

How a Jelly Bean Resets the Immune System

The SetPoint implant is a small titanium and ceramic pod containing a battery and a neurostimulator. A surgeon places it below the left collarbone under general anesthesia, with a lead running up to the left cervical vagus nerve.

Once in place, the device activates automatically, every day, for exactly 60 seconds.

That single minute of electrical stimulation travels up the vagus nerve to the brain, which relays a signal to the spleen. The spleen then reduces its production of TNF and other pro-inflammatory cytokines — the same proteins that drive joint destruction in RA. The process doesn’t suppress the immune system broadly. It recalibrates a specific pathway. The body isn’t being sedated; it’s being reminded how to regulate itself.

The device runs for up to 10 years. The only maintenance required is charging the implant battery for a few minutes each week — roughly as demanding as charging a toothbrush.

No monthly injections. No daily pills. No laboratory monitoring for liver toxicity, infection risk, or blood counts.

The Rollout Has Already Begun — and It’s Just Getting Started

SetPoint Medical raised $140 million to fund commercialization following FDA approval, and the company began introducing the system in select U.S. cities in the second half of 2025. Nationwide availability commenced in early 2026.

Susan Perry’s implant in Texas wasn’t a trial. It was a commercial procedure. She paid for it. She received it. And she hasn’t had a bad day since.

But the RA indication may turn out to be the least interesting part of this story.

SetPoint has already received FDA Investigational Device Exemption approval to study the device in relapsing-remitting multiple sclerosis (RRMS), with a multicenter, randomized, sham-controlled pilot study initiated in 2026 and enrolling up to 60 patients across the United States. The hypothesis: that vagus nerve stimulation may promote remyelination — the repair of the myelin sheath that MS progressively destroys.

The company is also evaluating the platform for Crohn’s disease. Earlier published data demonstrated the device’s effectiveness in reducing inflammatory bowel disease activity.

And the research community is watching something broader: early clinical evidence that vagus nerve stimulation improves symptoms in Parkinson’s disease, metabolic syndrome, type 2 diabetes, and Alzheimer’s disease.

All of these conditions share one thing: chronic inflammation as a root driver or major exacerbating factor.

What This Actually Means — and Who Needs to Hear It

More than 1.5 million Americans live with rheumatoid arthritis. Only 25% of RA patients report being satisfied with their current therapy. Up to half discontinue their prescribed medications within two years — because the drugs stop working, because the side effects become intolerable, or because they simply cannot afford them.

The biologic drug market for RA is dominated by medications that can cost $20,000 to $50,000 per year. They require cold-chain logistics, regular injections, and ongoing bloodwork. They blunt the immune system systemically, raising the risk of infection, certain cancers, and opportunistic illness. For tens of thousands of patients, they are also simply inadequate.

The SetPoint System is not cheap, and it requires surgery. That is a legitimate barrier, and the access and insurance coverage questions are not yet resolved. SetPoint Medical has said it is working with providers and payers to establish reimbursement pathways.

But the underlying premise — that a device can replace or supplement a drug by activating the body’s own regulatory biology — represents a category shift that the pharmaceutical industry has been unable or unwilling to pursue. There is no patent cliff on the vagus nerve. There is no generic competition to a neural pathway.

What there is, for the first time, is a cleared device that turns on the body’s anti-inflammatory switch, leaves the immune system otherwise intact, runs for a decade, and was validated in a rigorous sham-controlled trial.

For the rheumatology patients who have cycled through drug after drug, the message is simple: there is now a door that wasn’t there before.

Key Questions

Who qualifies for the SetPoint System? Adults with moderate-to-severe RA who have had an inadequate response to, or cannot tolerate, at least one biologic or targeted synthetic DMARD.

Is it covered by insurance? Coverage is being negotiated with major payers. Patients should contact SetPoint Medical directly or consult their rheumatologist about access programs.

Where is it available? Nationwide in the United States as of early 2026. International approvals are pending; the device is not yet available in most other countries.

What other diseases might this treat? Active or planned research includes relapsing-remitting MS, Crohn’s disease, inflammatory bowel disease, and exploratory work in Parkinson’s, Alzheimer’s, diabetes, and metabolic syndrome.

How long does the surgery take, and what is recovery like? The implant procedure is performed under general anesthesia. SetPoint Medical reports the procedure is well-tolerated with a low serious adverse event rate of 1.7%. Patients should consult with a qualified surgical center for specifics.